Neurol. praxi. 2021;22(3):176-181 | DOI: 10.36290/neu.2021.033

Novel approaches in pharmacological treatment of epilepsy

MUDr. Jana Zárubová, prof. MUDr. Petr Marusič, Ph.D.
Neurologická klinika 2. LF UK a FN Motol, Praha

In adults, 70-80 % of patients with epilepsy can be seizure free with pharmacological treatment. Novel approaches have been adopted in treatment strategies, new drugs have been introduced to the market and individualized precision therapy with a use of "orphan drugs" have been successfully used in few well characterized genetically determined epilepsies. In the treatment strategy, a short - and a long-term plan should be established to test systematically for the efficacy of different drugs. Buccal midazolam has been registered as a "rescue medication ". New drugs have been introduced recently for add-on therapy of focal seizures (perampanel, brivaracetam) or generalized tonic-clonic seizures (perampanel), some has been registered as an "orphan drug"(cannabidiol) for rare epilepsies, some has been registered (cenobamate) and their introduction to the market in the Czech Republic is expected in the future.

Keywords: epilepsy, seizure, treatment, antiepileptic drugs, antiseizure medication

Received: April 27, 2021; Revised: May 7, 2021; Accepted: May 7, 2021; Prepublished online: May 7, 2021; Published: October 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zárubová J, Marusič P. Novel approaches in pharmacological treatment of epilepsy. Neurol. praxi. 2021;22(3):176-181. doi: 10.36290/neu.2021.033.
Download citation

References

  1. Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E. A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia 2020; 61(8): 1668-1677. doi: 10.1111/epi.16610. Epub 2020 Jul 22. PMID: 32697354. Go to original source... Go to PubMed...
  2. Capovilla G, Kaufman KR, Perucca E, Moshé SL, Arida RM. Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy. Epilepsia 2016; 57(1): 6-12. doi: 10.1111/epi.13261. Epub 2015 Dec 10. PMID: 26662920. Go to original source... Go to PubMed...
  3. Centellas MF. Effectiveness and tolerability of perampanel in adolescents and adults as a first add-on therapy. An observational multicentre study. 71st Annual Meeting of the American Epilepsy Society, Washington, DC, USA. (2017, 12).
  4. Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav 2018; 86: 131-137. doi: 10.1016/j.yebeh.2018.05.013. Epub 2018 Jul 11. PMID: 30006259. Go to original source... Go to PubMed...
  5. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15(3): 270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Erratum in: Lancet Neurol. 2016; 15(4): 352. PMID: 26724101. Go to original source... Go to PubMed...
  6. Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Voi M, Fan J, Vaury A, Pelov D, French JA. Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial. Neurol Clin Pract 2018; 8(5): 412-420. doi: 10.1212/CPJ.0000000000000514. PMID: 30564495; PMCID: PMC6276348. Go to original source... Go to PubMed...
  7. Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis. Seizure 2018; 61: 98-103. doi: 10.1016/j.seizure.2018.07.017. Epub 2018 Jul 29. PMID: 30118932. Go to original source... Go to PubMed...
  8. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes inpatients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol 2018; 75: 279-86. Go to original source... Go to PubMed...
  9. Klein P, Laloyaux C, Elmoufti S, Gasalla T, Martin MS. Time course of 75%-100% efficacy response of adjunctive brivaracetam. Acta Neurol Scand 2020; 142(2): 175-180. doi: 10.1111/ane.13287. Epub 2020 Jun 9. PMID: 32432339; PMCID: PMC7422720. Go to original source... Go to PubMed...
  10. Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020; 19(1): 38-48. doi: 10.1016/S1474-4422(19)30399-0. Epub 2019 Nov 14. Erratum in: Lancet Neurol. 2020 Mar; 19(3): e3. PMID: 31734103. Go to original source... Go to PubMed...
  11. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser, W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069-1077. Go to original source... Go to PubMed...
  12. Liguori C, Izzi F, Manfredi N, D'Elia A, Mari L, Mercuri NB, Fabio P. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study. Epilepsy Behav 2018; 80: 173-176. doi: 10.1016/j.yebeh.2018.01.001. Epub 2018 Feb 3. PMID: 29414548. Go to original source... Go to PubMed...
  13. Marusič P, Ošlejšková H, Brázdil M, Brožová K, Hadač J, Hovorka J, Komárek V, Kršek P, Rektor I, Tomášek M, Vojtěch Z, Zárubová J. Nové klasifikace epileptických záchvatů a epilepsií ILAE 2017. Neurol. praxi 2018; 19(1): 32-36. doi: 10.36290/neu.2018.075 Go to original source...
  14. Marusič P, Zárubová J. Antiepileptika ve Farmakologie 2018. Grada Publishing. 228-242.
  15. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics 2015; 12(4): 747-68. doi: 10.1007/s13311-015-0375-5. PMID: 26282273; PMCID: PMC4604191. Go to original source... Go to PubMed...
  16. Volná K, Kočvarová J, Zárubová J, Krijtová H, Novotná I, Tomášek M, Rektor I, Elišák M, Doležalová I, Fábera 1, Pail M, Kalina A, Martinkovič L, Šulc V, Brázdil M, Marusič P. Efektivita a tolerance perampanelu - multicentrická studie. 31. český a slovenský neurologický sjezd, 22.-25. 11. 2017.
  17. Zárubová J, Marusič P. Epilepsie dospělých s přetrvávajícími záchvaty - jak postupovat. Neurol. praxi 2019; 20(4): 307-311. doi: 10.36290/neu.2019.133 Go to original source...
  18. Zárubová J. Farmakoterapie epilepsií z pohledu neurologa, epileptologa. Klin Farmakol Farm 2019; 33(2): 30-35. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.